- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Capricor Therapeutics Sees Surge in Trading Volume
Shares of the biotech firm jumped nearly 15% on Tuesday amid increased investor interest.
Published on Mar. 10, 2026
Got story updates? Submit your updates here. ›
Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on developing cell and exosome-based therapies, saw a significant increase in trading volume on Tuesday. The stock traded 2,454,245 shares, up 95% from the previous session's volume of 1,258,353 shares. Capricor's share price closed at $35.22, up nearly 15% from the previous close of $30.63.
Why it matters
The surge in trading volume and share price for Capricor Therapeutics suggests increased investor interest and confidence in the company's pipeline of cell and exosome-based therapies, particularly its lead candidate CAP-1002 which is being evaluated for Duchenne muscular dystrophy and COVID-19-related heart injury. As a clinical-stage biotech, Capricor's stock performance and trading activity are closely watched by investors and analysts.
The details
Several research firms have recently issued reports on Capricor Therapeutics, with some mixed ratings. Weiss Ratings maintained a 'sell (e+)' rating on the stock, while Wall Street Zen downgraded it from 'hold' to 'sell'. However, iA Financial set a $48.00 target price, and Cantor Fitzgerald reaffirmed an 'overweight' rating. Overall, the company has a consensus 'Moderate Buy' rating from analysts, with a consensus price target of $40.82.
- The trading volume surge occurred on Tuesday, March 10, 2026.
The players
Capricor Therapeutics, Inc.
A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases. The company is headquartered in Beverly Hills, California.
Weiss Ratings
A research firm that maintained a 'sell (e+)' rating on Capricor Therapeutics' stock.
Wall Street Zen
A research firm that downgraded Capricor Therapeutics' stock from 'hold' to 'sell'.
iA Financial
A research firm that set a $48.00 target price on Capricor Therapeutics' stock.
Cantor Fitzgerald
A research firm that reaffirmed an 'overweight' rating on Capricor Therapeutics' stock.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
The takeaway
The surge in trading volume and share price for Capricor Therapeutics highlights the biotech industry's volatility and the importance of closely following research firm ratings and price targets when evaluating investment opportunities in the sector.
